Showing results (41-50 of 129) with videos related to

Sort By:
Pageof 13
Cancer|June 1, 1986
Successful management of metastatic and primary germ cell tumors in the brainG J Rustin, E S Newlands, K D Bagshawe, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|March 1, 1991
Optimum management of pineal germ cell tumoursD B Smith, E S Newlands, R H Begent, et al.
British Journal of Cancer|February 1, 1989
The effect of intensity of administered treatment on the outcome of germ cell tumours treated with POMB/ACE chemotherapyS M Crawford, E S Newlands, R H Begent, et al.
Cancer|November 1, 1983
Central nervous system metastases of choriocarcinoma. 23 years' experience at Charing Cross HospitalA Athanassiou, R H Begent, E S Newlands, et al.
International Journal of Cancer|March 12, 1991
A phase-I study of repeated therapy with radiolabelled antibody to carcinoembryonic antigen using intermittent or continuous administration of cyclosporin A to suppress the immune responseJ A Ledermann, R H Begent, C Massof, et al.
British Journal of Cancer|January 1, 1995
Galactosylated streptavidin for improved clearance of biotinylated intact and F(ab')2 fragments of an anti-tumour antibodyD Marshall, R B Pedley, R G Melton, et al.
British Journal of Cancer|March 1, 1996
Polyethylene glycol modification of a galactosylated streptavidin clearing agent: effects on immunogenicity and clearance of a biotinylated anti-tumour antibodyD Marshall, R B Pedley, J A Boden, et al.
British Journal of Obstetrics and Gynaecology|January 1, 1986
Developments in chemotherapy for medium- and high-risk patients with gestational trophoblastic tumours (1979-1984)E S Newlands, K D Bagshawe, R H Begent, et al.
International Journal of Cancer|February 20, 1991
The effect of radiosensitizers on radio-immunotherapy, using 131I-labelled anti-CEA antibodies in a human colonic xenograft modelR B Pedley, R H Begent, J A Boden, et al.
Radiation Research|June 22, 2001
A mouse model for calculating the absorbed beta-particle dose from (131)I- and (90)Y-labeled immunoconjugates, including a method for dealing with heterogeneity in kidney and tumorA A Flynn, A J Green, R B Pedley, et al.
Pageof 13